What is the recommended dosage and usage of mefenamic acid for pain management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mefenamic Acid Dosage and Usage for Pain Management

For pain management, mefenamic acid should be administered at 500 mg as an initial dose followed by 250 mg every 6 hours as needed, usually not exceeding one week of use. 1

Indications and Formulations

Mefenamic acid is a non-steroidal anti-inflammatory drug (NSAID) available in capsule form (250-500 mg) with the following key characteristics:

  • Time to onset: approximately 30+ minutes 2
  • Maximum daily dose: 4 × 500 mg (2000 mg total) 2
  • Primary cautions: Gastrointestinal and renal toxicity 2

Specific Dosing Recommendations by Condition

Acute Pain

  • Initial dose: 500 mg
  • Maintenance dose: 250 mg every 6 hours as needed
  • Maximum duration: Usually not to exceed one week 1

Primary Dysmenorrhea

  • Initial dose: 500 mg
  • Maintenance dose: 250 mg every 6 hours
  • Timing: Start with onset of menstrual bleeding and associated symptoms
  • Duration: Typically not necessary for more than 2-3 days 1

Efficacy Evidence

Mefenamic acid has demonstrated effectiveness in:

  1. Acute postoperative pain: The Number Needed to Treat (NNT) for at least 50% pain relief over 6 hours with a single dose of mefenamic acid 500 mg compared to placebo was 4.0 3

  2. Primary dysmenorrhea: Studies show complete relief of all symptoms in 88.6% of patients when administered at 500 mg every 8 hours for up to 3 days during menstruation 4

Safety Considerations

  • Use the lowest effective dose for the shortest duration consistent with individual treatment goals 1
  • Monitor for gastrointestinal bleeding, ulceration, and perforation 1
  • Exercise caution in patients with:
    • History of gastrointestinal disorders
    • Renal impairment
    • Cardiovascular disease

Comparison with Other Analgesics

Mefenamic acid is classified as a WHO Step I analgesic (for mild pain) 2. In the WHO pain ladder approach:

  • For mild pain (NRS: 1-4): Non-opioid analgesics like mefenamic acid are recommended
  • For moderate pain (NRS: 5-7): Consider combining with weak opioids
  • For severe pain: Strong opioids are typically required

Important Caveats

  • Mefenamic acid should not be used for longer than one week for acute pain management due to increased risk of adverse effects 1
  • For primary dysmenorrhea, limiting use to 2-3 days per menstrual cycle is recommended 1
  • Some studies suggest that other NSAIDs may have better efficacy profiles for certain conditions 5, 6
  • Always consider gastroprotection when NSAIDs are used over a prolonged period 2

Monitoring

  • Monitor for signs of gastrointestinal bleeding or ulceration
  • Assess renal function periodically during extended use
  • Evaluate pain control and adjust dosing as needed within the recommended parameters

When prescribing mefenamic acid, carefully weigh the potential benefits against risks, particularly in patients with pre-existing gastrointestinal or renal conditions.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Single dose oral mefenamic acid for acute postoperative pain in adults.

The Cochrane database of systematic reviews, 2011

Research

Treatment of primary dysmenorrhea with mefenamic acid.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 1980

Research

Effect of alpha-lipoic acid at the combination with mefenamic acid in girls with primary dysmenorrhea: randomized, double-blind, placebo-controlled clinical trial.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.